Medical Cannabis - Pharmacology
Phytocannabinoids: THC, CBD, CBG, CBN, and More
Pharmacology and Clinical Application
Phytocannabinoids are the active compounds of Cannabis sativa that interact with the human Endocannabinoid System. Understanding their pharmacology, mechanisms of action, safety profiles, and drug-drug interactions is indispensable for rational, safe, and effective prescribing in clinical practice.
Table of Contents
- Biosynthesis: from CBGA to active cannabinoids
- Acidic forms and decarboxylation
- THC: pharmacology, clinical effects, and safety
- CBD: the non-psychotropic modulator
- Pharmacological interactions of CBD (CYP450)
- Minor cannabinoids: CBG, CBN, CBC
- Propyl variants: THCV and CBDV
- The Entourage Effect
- Clinical THC:CBD ratios — a prescribing tool
- Clinical decision algorithm
Biosynthesis: From CBGA to Active Cannabinoids
Phytocannabinoids are secondary metabolites of Cannabis sativa synthesized exclusively within the plant's glandular trichomes. Their production follows a precise biosynthetic pathway that begins with two metabolic precursors — hexanoic acid and geranyl pyrophosphate (GPP) — and converges into a single foundational intermediate: CBGA (cannabigerolic acid), widely termed "the mother cannabinoid."
— Module 2, Topic 2. Medical Cannabis Course for Healthcare Professionals. Receta Cannabis, 2025.From CBGA, three specific synthase enzymes catalyze the formation of the three primary acidic cannabinoids, which are subsequently converted into pharmacologically active neutral cannabinoids through decarboxylation:
Clinical relevance of CBGA: CBGA is not merely a metabolic intermediate; it exhibits distinct pharmacological properties (including anti-inflammatory, antimicrobial, and potential neuroprotective activities) that are under active investigation. The proportion of CBGA channeled into THCA, CBDA, or CBCA is genetically determined by the relative expression of each synthase, underlying the natural chemical variability among Cannabis cultivars.
Acidic Forms and Decarboxylation: Key to Activation
A fundamental — and frequently misunderstood — principle of cannabinoid pharmacology is that the living plant contains virtually no THC or CBD. It synthesizes their carboxylated acidic precursors (THCA and CBDA), which are pharmacologically distinct and lack the therapeutic and psychotropic profiles of their neutral counterparts. Converting them requires thermal energy through the process of decarboxylation.
- Non-psychotropic in their native acidic state
- Low blood-brain barrier permeability
- Distinct pharmacological profiles: anti-inflammatory, neuroprotective, potent antiemetic (CBDA)
- Naturally found in cold-pressed raw Cannabis juice
- Emerging clinical research regarding their independent therapeutic potential
THC: 157°C · CBD: 160–180°C
- Pharmacologically active at CB1 and CB2 receptors
- High blood-brain barrier permeability (notably THC)
- Near-instantaneous activation upon vaporization
- Very slow, incomplete spontaneous conversion at ambient storage temperatures
- Complete conversion achieved in thermally processed extracts and pharmaceutical preparations
Direct clinical takeaway: When prescribing medicinal Cannabis oils or standardized extracts, it is vital to confirm whether the product has undergone complete decarboxylation (containing active neutral THC/CBD) or represents a raw extract (retaining THCA/CBDA). Non-decarboxylated formulas will not yield the expected therapeutic outcomes associated with active THC. Most authorized cannabinoid medicines in Europe rely strictly on activated neutral cannabinoids.
THC (Δ⁹-Tetrahydrocannabinol): Comprehensive Pharmacology
Δ⁹-Tetrahydrocannabinol (THC) is the primary psychoactive cannabinoid in Cannabis sativa and the most comprehensively researched phytocannabinoid. Its structural isolation and total synthesis by Raphael Mechoulam and Yechiel Gaoni in 1964 established the foundation of modern cannabinoid science. Beyond its recreational notoriety, THC displays an extensive, evidence-based therapeutic profile that supports its clinical prescription for specific indications under disciplined medical supervision.
- Analgesia: Neuropathic, central, and oncological pain — dampens nociceptive signals via spinal and supraspinal CB1 receptors
- Antiemetic: Manages chemotherapy-induced nausea and vomiting (CINV) — acts on CB1 receptors in the brainstem area postrema
- Orexigenic: Stimulates appetite in HIV/AIDS- and cancer-associated cachexia — activates hypothalamic CB1 signaling
- Antispasmodic: Reduces spasticity and muscle rigidity in Multiple Sclerosis — mediated by inhibitory CB1 motor circuitry
- Sleep architecture: Decreases sleep latency and nocturnal awakenings at titrated low doses
- Acute: Sinus tachycardia, orthostatic hypotension, sedation, transient acute anxiety or paranoia (especially in cannabinoid-naïve patients)
- Cognitive: Reversible, dose-dependent blunting of short-term working memory, processing speed, and sustained attention
- Chronic risks: Pharmacodynamic tolerance, physical dependence (~9% in long-term regular users), mild withdrawal syndrome
- Cannabinoid Hyperemesis Syndrome: Paradoxical cyclical vomiting linked to heavy, chronic high-dose use
- Psychiatric vulnerability: May unmask or exacerbate psychotic disorders in genetically predisposed individuals (e.g., COMT variants)
Personal or immediate family history of schizophrenia or other primary psychotic disorders · Unstable coronary artery disease or serious cardiac arrhythmias · Active pregnancy and breastfeeding · Patients under 25 years of age (except in refractory pediatric neurological syndromes) · Documented hypersensitivity to THC.
Active metabolite 11-OH-THC: Upon ingestion, hepatic first-pass metabolism (primarily via CYP2C9 and CYP3A4) converts THC into 11-hydroxy-THC (11-OH-THC), an active metabolite exhibiting higher blood-brain barrier permeability and heightened CB1 potency compared to parent THC. This pharmacokinetic transformation accounts for the delayed onset, intensified psychoactive profile, and extended duration typical of oral formulations (oils, capsules) relative to inhalation.
Cardiovascular safety considerations: The relative scarcity of CB1 receptors in the brainstem respiratory nuclei accounts for the absence of fatal central respiratory depression from THC, providing a favorable safety margin compared to opioid analgesics. Nonetheless, vascular CB1 activation causes reflex tachycardia and orthostatic hypotension, which can present significant clinical risks in patients with pre-existing ischemic heart disease, heart failure, or concurrent antihypertensive regimens. Baseline cardiovascular risk must always be assessed prior to initiating THC.
CBD (Cannabidiol): The Non-Psychotropic Modulator
Cannabidiol (CBD) is the second most abundant cannabinoid in Cannabis sativa and the compound that has gathered the greatest therapeutic interest over the past decade. Unlike THC, CBD produces no intoxicating or psychotropic effects and displays an exceptionally favorable safety profile. Its pharmacodynamics are intricate and multimodal: it engages at least six distinct receptor and channel systems, explaining its diverse clinical utility.
- CB1 negative allosteric modulator: Alters receptor conformation without orthosteric activation, blunting THC binding affinity — pharmacological basis for CBD's mitigation of THC-induced tachycardia and paranoia
- 5-HT1A receptor agonist: Exerts direct anxiolytic and neuroprotective responses via serotonin pathways
- TRPV1 receptor agonist: Desensitizes peripheral nociceptive ion channels, contributing to analgesia
- FAAH enzyme inhibitor: Slows enzymatic breakdown of endogenous anandamide, enhancing endocannabinoid tone
- GPR55 antagonist: Modulates neuronal excitability (anticonvulsant activity) and bone resorption
- Refractory pediatric epilepsy: Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex — authorized by the EMA and FDA (Epidyolex®)
- Anxiety disorders: Generalized anxiety disorder, PTSD, and social phobia — supported by solid clinical and experimental data
- Systemic inflammatory conditions: Rheumatoid arthritis, inflammatory bowel disease — confirmed in preclinical and emerging clinical models
- Neuropathic pain: Highly effective in balanced combination with THC (1:1 ratio)
- Sleep disturbances: Improves sleep efficiency primarily by alleviating underlying pain and anxiety
Does not cause respiratory depression · Devoid of addictive or abuse liability · Does not induce significant pharmacological tolerance · Most common adverse effects are mild (diarrhea, somnolence, decreased appetite, primarily noted at high doses >300 mg/day) · Primary clinical risk: drug-drug interactions via hepatic CYP450 inhibition — reviewed below.
Pharmacological Interactions of CBD: The CYP450 System
The single most important drug interaction associated with CBD in clinical practice stems from its potent capacity to inhibit CYP3A4 and CYP2C19 enzymes within the hepatic cytochrome P450 cascade. These pathways clear roughly 60% of all clinically prescribed pharmaceuticals. Competitive inhibition by CBD can substantially elevate serum concentrations of co-administered drugs, heightening the risk of clinical toxicity.
| Co-administered Drug | Metabolic Pathway | Clinical Impact | Recommended Monitoring |
|---|---|---|---|
| Warfarin | CYP2C9 | ↑ INR — significant bleeding risk | Weekly INR at initiation; titrate warfarin downward |
| Clobazam | CYP3A4 / CYP2C19 | ↑ Active metabolite — profound sedation, ataxia | Reduce clobazam dose by 25–50%; monitor alertness |
| Valproic Acid (Sodium Valproate) | Non-CYP synergistic pathway | ↑ Serum transaminases — risk of liver injury | Monthly hepatic panel (ALT/AST, bilirubin); crucial in pediatrics |
| Tacrolimus / Cyclosporine | CYP3A4 | ↑ Plasma levels — nephrotoxicity and immunosuppressive toxicity | Routine therapeutic drug monitoring (TDM); preemptive dose adjustments |
| Statins (e.g., Simvastatin, Atorvastatin) | CYP3A4 | ↑ Bioavailability — elevated risk of myopathy and rhabdomyolysis | Monitor creatine kinase and muscle pain; consider non-CYP3A4 statin (e.g., Rosuvastatin) |
Fundamental prescribing rule: Before initiating CBD therapy, clinicians must conduct a systematic medication review targeting drugs cleared via CYP3A4 or CYP2C19. Medications with a narrow therapeutic index (anticoagulants, anticonvulsants, calcineurin inhibitors) warrant rigorous therapeutic drug monitoring. This inhibitory interaction is dose-dependent: while low daily doses (<150 mg/day) carry low risk, high-dose regimens (>300 mg/day) regularly cause clinically meaningful pharmacokinetic shifts.
CBG, CBN, and CBC: Minor Cannabinoids with Clinical Potential
Beyond THC and CBD, Cannabis sativa contains more than 100 identified phytocannabinoids. Although present in minor botanical quantities, these "minor cannabinoids" possess distinctive molecular targets and growing clinical interest. While human clinical trials remain in early phases, preclinical data highlight significant future therapeutic applications.
- Potent α2-adrenergic agonist — modulates vascular tone and sympathetic outflow
- Moderate 5-HT1A antagonist — functional profile distinct from CBD
- GABA reuptake inhibitor — potential centrally mediated anxiolytic effects
- Direct antimicrobial action against Gram-positive pathogens (including MRSA)
- Glaucoma: Lowers intraocular pressure (IOP) via improved trabecular outflow
- Inflammatory Bowel Disease: Attenuates intestinal inflammation in colitis models
- Neuroprotection: Shown to preserve striatal neurons in Huntington's disease models
- Antimicrobial: Demonstrates efficacy against multi-drug resistant strains
Data remain largely preclinical (in vitro and in vivo animal assays); controlled human trials are limited. Natural extraction yields are low because the plant rapidly converts CBG into downstream cannabinoids, making purified formulations costly.
- Forms non-enzymatically through prolonged heat, light, and oxidation of THC
- Retains weak affinity for CB1/CB2 (~10% the potency of parent THC)
- Allosteric modulation at peripheral TRPV2 and TRPA1 receptors
- Mild sedative actions, markedly amplified when combined with myrcene
- Sleep disorders: Widely cited for sedative properties, though clinical evidence remains mixed
- Analgesia: Displays antinociceptive action via peripheral TRPA1 desensitization
- Anti-inflammatory: Reduces synovial inflammation in experimental arthritis models
- Antibacterial: Exhibits potent activity against resistant staphylococci
While commercial formulations frequently market CBN as a powerful sleep aid, rigorously controlled monotherapy human trials remain scarce. The sedation seen with aged, CBN-rich Cannabis is likely driven by synergistic interactions with sedative terpenes (myrcene, linalool) rather than isolated CBN.
- Selective agonist of TRPA1 and TRPV4 nociceptive channels
- Negligible binding affinity for classic CB1/CB2 receptors
- Indirectly raises local anandamide levels by inhibiting cellular reuptake
- Modulates postsynaptic 5-HT1A serotonergic transmission
- Adult neurogenesis: Promotes neural stem/progenitor cell viability and differentiation
- Depressive symptoms: Exhibits marked antidepressant-like effects in animal paradigms
- Dermatology: Suppresses sebaceous lipid synthesis and alleviates cutibacterium-induced acne
- Analgesic synergy: Enhances the antinociceptive efficacy of THC and CBD in pain models
CBC stands out in preclinical neuroscience and dermatology, yet human clinical trials are almost entirely absent. Clinical use currently relies on its presence as an entourage component within broad- and full-spectrum extracts.
THCV and CBDV: The Propyl Variants of Emerging Interest
Propyl cannabinoids differ from traditional cannabinoids (THC, CBD) by the length of their alkyl side chain: they possess a 3-carbon propyl chain rather than the standard 5-carbon pentyl chain. This subtle structural alteration leads to markedly different pharmacodynamic profiles with direct therapeutic relevance.
- Low doses: Neutral antagonist at CB1 — suppresses appetite, non-psychoactive, rapid onset
- High doses: Partial agonist at CB1 — psychoactive, with faster onset and shorter half-life than THC
- Agonist at CB2 receptors across all dosing ranges — anti-inflammatory profile
- Engages peripheral TRPV1 and GPR55 pathways
- Type 2 Diabetes: Improves insulin sensitivity, preserves pancreatic beta-cell function, and lowers fasting glycemia in Phase II trials
- Metabolic syndrome & obesity: Appetite suppressant without the dysphoria of synthetic CB1 inverse agonists
- Epilepsy: Demonstrated anticonvulsant activity in animal seizure models
- Parkinson's Disease: Displays neuroprotective and symptom-modulating benefits in motor models
THCV represents a compelling candidate for cardiometabolic disorders. Its ability to improve glycemic control without triggering the hyperphagic drive of THC makes it an active target in clinical development, supported by positive early-phase human trials.
- Similar molecular targets to CBD, with differing receptor binding affinities
- Agonist of TRPV1 and TRPA1, mediating stabilization of hyperexcitable neuronal membranes
- Modulates central GABAergic transmission, promoting anxiolytic responses
- Non-intoxicating — no functional recruitment of central CB1 receptors
- Epilepsy: Displays broad-spectrum anticonvulsant activity across drug-resistant models
- Autism Spectrum Disorder (ASD): Ongoing clinical trials evaluating improvements in repetitive behaviors and social communication
- Nausea & emesis: Documented antiemetic activity in preclinical settings
- Neuropathic pain: Promising efficacy in reducing mechanical hyperalgesia
CBDV has advanced through Phase II clinical programs for pediatric epilepsy syndromes and Autism Spectrum Disorder. Its safety and tolerability profile closely mirror those of purified CBD.
The Entourage Effect: Whole-Plant Synergy
Originally described by Raphael Mechoulam and Shimon Ben-Shabat in 1998 and later expanded by Ethan Russo in 2011, the "Entourage Effect" posits that Cannabis constituents act synergistically: whole-plant extracts frequently exhibit superior clinical efficacy and fewer adverse effects than isolated, single-molecule cannabinoids. This synergy plays a crucial role when selecting products for clinical care.
The Entourage Effect describes the pharmacodynamic synergy whereby full-spectrum Cannabis extracts provide broader therapeutic efficacy than the sum of their individual isolated constituents — whether isolated cannabinoids, terpenes, or synthetic monotherapies.
— Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.- Myrcene: Enhances blood-brain barrier permeability, promoting central cannabinoid uptake; possesses independent analgesic and muscle-relaxant properties
- Limonene: Anxiolytic and pro-dopaminergic; facilitates 5-HT1A activity to alleviate stress and mood disturbances
- Linalool: Sedative, anticonvulsant, and local anesthetic via central GABAergic amplification
- β-Caryophyllene: Directly acts as a selective CB2 receptor agonist without engaging CB1; potent gastroprotective and anti-inflammatory agent
- α-Pinene: Natural bronchodilator and acetylcholinesterase inhibitor; helps counteract short-term memory impairment induced by THC
- Full Spectrum: Contains the complete spectrum of native cannabinoids, terpenes, and flavonoids. Maximizes synergistic clinical benefits. Contains trace or active THC (relevant for drug screenings or sensitive patients)
- Broad Spectrum: Full botanical extract with THC selectively removed to below detectable limits. Retains terpene synergy without psychoactive or regulatory concerns regarding THC
- Isolate: Purified single molecule (≥99% CBD or THC). Lacks botanical synergy, but allows precise milligram-level dosing and ensures zero exposure to other compounds
- Clinical guideline: For most chronic, non-pediatric conditions, full- or broad-spectrum formulations provide greater therapeutic utility per milligram than single-molecule isolates
Clinical evidence supporting the Entourage Effect: A meta-analysis by Pamplona et al. (2018) in patients with refractory epilepsy revealed that full-spectrum CBD-rich extracts achieved clinical seizure control at doses nearly four times lower than purified CBD isolates (6.0 mg/kg/day vs. 25.3 mg/kg/day), while causing significantly fewer adverse events. This provides quantitative evidence for botanical synergy in human therapeutics.
Clinical THC:CBD Ratios — The Primary Prescribing Tool
The THC:CBD ratio is the foundational parameter in medical Cannabis prescribing. It determines the therapeutic index, analgesic efficacy, and degree of psychoactivity. The ratio must be selected based on the clinical diagnosis, comorbidities, and the patient's prior cannabinoid exposure. The overarching clinical maxim is "Start low, go slow": initiate at minimal doses and titrate gradually every 3 to 7 days.
Patient profile: Adults with prior cannabinoid exposure, no personal or family history of psychosis, and stable cardiovascular function.
Patient profile: Standard first-line option for most adult presentations. The co-administered CBD attenuates THC-induced tachycardia and anxiety.
Patient profile: Pediatric populations, THC-sensitive individuals, professionals requiring uncompromised cognitive function.
| Clinical Indication | Recommended Starting Ratio | Pharmacological Rationale | Reference Medication |
|---|---|---|---|
| Refractory Epilepsy (Dravet/LGS) | High CBD (<1:20) | CBD provides primary multimodal anticonvulsant activity; high-dose THC may lower seizure thresholds | Epidyolex® (Purified CBD oral solution) |
| Chronic Neuropathic Pain | Balanced (1:1) | THC/CBD synergy on ascending nociceptive pathways; CBD reduces THC-mediated psychoactivity | Sativex® (Nabiximols 1:1 oromucosal spray) |
| Multiple Sclerosis Spasticity | Balanced (1:1) | Approved indication for Sativex® — Level I clinical evidence | Sativex® (Nabiximols 1:1 oromucosal spray) |
| Chemotherapy-Induced Nausea & Vomiting (CINV) | High THC (>10:1) | THC drives antiemetic signaling via area postrema CB1 activation | Dronabinol, Nabilone |
| Severe Anxiety / PTSD | High CBD (<1:10) | CBD promotes 5-HT1A agonism; high-dose THC can worsen anxiety and trigger panic | Compounded standardized CBD oils |
| Chronic Insomnia | THC-dominant + CBN | THC shortens sleep latency; CBN and myrcene support sedation | Standardized magistral formulations |
Clinical Decision Algorithm for Cannabinoid Prescribing
Prescribing medical Cannabis requires a structured, step-by-step approach that evaluates the therapeutic goal, screens for patient-specific risks, selects the appropriate chemical profile, and follows a disciplined titration schedule. The following 4-step algorithm outlines this decision-making process based on current clinical consensus.
Regulatory framework in Spain (Royal Decree 903/2025): The prescription of medicinal Cannabis in Spain must adhere strictly to Royal Decree 903/2025, which governs authorized cannabinoid pharmaceutical specialties (Sativex®, Epidyolex®) and standardized compounded magistral preparations. Prescribing physicians bear direct responsibility for clinical indications, dosing oversight, and ongoing pharmacovigilance. Clinicians must consult current regional healthcare guidelines prior to prescribing.
Comparative Table of Major Phytocannabinoids
| Cannabinoid | Psychoactivity | Primary Molecular Targets | Primary Clinical Indications | Level of Clinical Evidence |
|---|---|---|---|---|
| THC | Marked ✗ | Partial agonist at CB1 / CB2 | Neuropathic pain, spasticity, CINV, cachexia | High (Multiple Phase III RCTs) |
| CBD | None ✓ | CB1 allosteric modulator, 5-HT1A, TRPV1, GPR55 | Refractory epilepsy, anxiety, systemic inflammation | High (Approved EMA/FDA indications) |
| CBG | None ✓ | α2-Adrenergic agonist, 5-HT1A antagonist | Glaucoma, IBD, neurodegenerative models (potential) | Low (Predominantly preclinical) |
| CBN | Minimal ≈ | Weak CB1/CB2 agonist, TRPA1/TRPV2 | Sedation, sleep maintenance, analgesia (potential) | Very Low (Inconclusive human data) |
| CBC | None ✓ | TRPA1 / TRPV4 agonist, anandamide uptake inhibitor | Neurogenesis, mood regulation, inflammatory acne (potential) | Low (Predominantly preclinical) |
| THCV | Dose-dependent ⚡ | CB1 antagonist (low dose) / agonist (high dose) | Type 2 Diabetes, obesity, metabolic syndrome | Moderate (Phase II clinical trials) |
| CBDV | None ✓ | TRPV1, TRPA1, GABA modulator | Intractable epilepsy, Autism Spectrum Disorder | Moderate (Phase II clinical trials) |
Key Takeaways for Medical Practice
Scientific References
- Mechoulam R, Gaoni Y. A total synthesis of dl-Δ1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc. 1965;87(14):3273–3275. doi:10.1021/ja01092a065
- Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–1364. doi:10.1111/j.1476-5381.2011.01238.x
- Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich Cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759. doi:10.3389/fneur.2018.00759
- Devinsky O, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–2020. doi:10.1056/NEJMoa1611618
- Whiting PF, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473. doi:10.1001/jama.2015.6358
- Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139–154. doi:10.1089/can.2016.0034
- Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod. 2017;103:103–131. doi:10.1007/978-3-319-45541-9_4
- Jadoon KA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes. Diabetes Care. 2016;39(10):1777–1786. doi:10.2337/dc16-0650